Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

被引:166
作者
George, Angela [1 ,2 ,3 ]
Riddell, Daniel [1 ]
Seal, Sheila [1 ,4 ]
Talukdar, Sabrina [1 ,4 ]
Mahamdallie, Shazia [1 ,4 ]
Ruark, Elise [1 ]
Cloke, Victoria [4 ]
Slade, Ingrid [5 ]
Kemp, Zoe [2 ]
Gore, Martin [3 ]
Strydom, Ann [1 ,4 ]
Banerjee, Susana [3 ]
Hanson, Helen [1 ,2 ]
Rahman, Nazneen [1 ,2 ,4 ]
机构
[1] Inst Canc Res, Div Genet & Epidemiol, London, England
[2] Royal Marsden NHS Fdn Trust, Canc Genet Unit, London, England
[3] Royal Marsden NHS Fdn Trust, Gynaecol Canc Unit, London, England
[4] Inst Canc Res, TGLclin, London, England
[5] Univ Oxford, NHS Hosp Trust, Oxford, England
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
基金
英国惠康基金;
关键词
BRCA2; MUTATIONS; GYNECOLOGIC CANCER; PARP INHIBITORS; WOMEN; MANAGEMENT; CARCINOMA; PATTERNS; BREAST;
D O I
10.1038/srep29506
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15% of ovarian cancer patients have a germline BRCA1 or BRCA2 mutation which has substantial implications for their personal management and that of their relatives. Unfortunately, in most countries, routine implementation of BRCA testing for ovarian cancer patients has been inconsistent and largely unsuccessful. We developed a rapid, robust, mainstream genetic testing pathway in which testing is undertaken by the trained cancer team with cascade testing to relatives performed by the genetics team. 207 women with ovarian cancer were offered testing through the mainstream pathway. All accepted. 33 (16%) had a BRCA mutation. The result informed management of 79% (121/154) women with active disease. Patient and clinician feedback was very positive. The pathway offers a 4-fold reduction in time and 13-fold reduction in resource requirement compared to the conventional testing pathway. The mainstream genetic testing pathway we present is effective, efficient and patient-centred. It can deliver rapid, robust, large-scale, cost-effective genetic testing of BRCA1 and BRCA2 and may serve as an exemplar for other genes and other diseases.
引用
收藏
页数:8
相关论文
共 35 条
[1]   BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].
Alsop, Kathryn ;
Fereday, Sian ;
Meldrum, Cliff ;
deFazio, Anna ;
Emmanuel, Catherine ;
George, Joshy ;
Dobrovic, Alexander ;
Birrer, Michael J. ;
Webb, Penelope M. ;
Stewart, Colin ;
Friedlander, Michael ;
Fox, Stephen ;
Bowtell, David ;
Mitchell, Gillian .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663
[2]   Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[3]   PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond [J].
Banerjee, Susana ;
Kaye, Stan .
CURRENT ONCOLOGY REPORTS, 2011, 13 (06) :442-449
[4]   Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer [J].
Candido-dos-Reis, Francisco J. ;
Song, Honglin ;
Goode, Ellen L. ;
Cunningham, Julie M. ;
Fridley, Brooke L. ;
Larson, Melissa C. ;
Alsop, Kathryn ;
Dicks, Ed ;
Harrington, Patricia ;
Ramus, Susan J. ;
de Fazio, Anna ;
Mitchell, Gillian ;
Fereday, Sian ;
Bolton, Kelly L. ;
Gourley, Charlie ;
Michie, Caroline ;
Karlan, Beth ;
Lester, Jenny ;
Walsh, Christine ;
Cass, Ilana ;
Olsson, Hakan ;
Gore, Martin ;
Benitez, Javier J. ;
Garcia, Maria J. ;
Andrulis, Irene ;
Mulligan, Anna Marie ;
Glendon, Gord ;
Blanco, Ignacio ;
Lazaro, Conxi ;
Whittemore, Alice S. ;
McGuire, Valerie ;
Sieh, Weiva ;
Montagna, Marco ;
Alducci, Elisa ;
Sadetzki, Siegal ;
Chetrit, Angela ;
Kwong, Ava ;
Kjaer, Susanne K. ;
Jensen, Allan ;
Hogdall, Estrid ;
Neuhausen, Susan ;
Nussbaum, Robert ;
Daly, Mary ;
Greene, Mark H. ;
Mai, Phuong L. ;
Loud, Jennifer T. ;
Moysich, Kirsten ;
Toland, Amanda E. ;
Lambrechts, Diether ;
Ellis, Steve .
CLINICAL CANCER RESEARCH, 2015, 21 (03) :652-657
[5]   Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy [J].
Chen, Ping ;
Huhtinen, Kaisa ;
Kaipio, Katja ;
Mikkonen, Piia ;
Aittomaki, Viljami ;
Lindell, Rony ;
Hynninen, Johanna ;
Auranen, Annika ;
Grenman, Seija ;
Lehtonen, Rainer ;
Carpen, Olli ;
Hautaniemi, Sampsa .
CANCER RESEARCH, 2015, 75 (15) :2987-2998
[6]   Olaparib: First Global Approval [J].
Deeks, Emma D. .
DRUGS, 2015, 75 (02) :231-240
[7]   Keeping it simple: Genetics referrals for all invasive serous ovarian cancers [J].
Demsky, R. ;
McCuaig, J. ;
Maganti, M. ;
Murphy, K. J. ;
Rosen, B. ;
Armel, S. R. .
GYNECOLOGIC ONCOLOGY, 2013, 130 (02) :329-333
[8]   BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance [J].
Eccles, D. M. ;
Mitchell, G. ;
Monteiro, A. N. A. ;
Schmutzler, R. ;
Couch, F. J. ;
Spurdle, A. B. ;
Gomez-Garcia, E. B. .
ANNALS OF ONCOLOGY, 2015, 26 (10) :2057-2065
[9]   A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO [J].
Evans, DGR ;
Eccles, DM ;
Rahman, N ;
Young, K ;
Bulman, M ;
Amir, E ;
Shenton, A ;
Howell, A ;
Lalloo, F .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (06) :474-480
[10]   Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals [J].
Febbraro, Terri ;
Robison, Katina ;
Wilbur, Jennifer Scalia ;
Laprise, Jessica ;
Bregar, Amy ;
Lopes, Vrishali ;
Legare, Robert ;
Stuckey, Ashley .
GYNECOLOGIC ONCOLOGY, 2015, 138 (01) :109-114